Literature DB >> 16053938

Therapeutic effects of Ag85B and MPT64 DNA vaccines in a murine model of Mycobacterium tuberculosis infection.

Daoyin Zhu1, Shan Jiang, Xudong Luo.   

Abstract

A new improved therapeutic strategy for tuberculosis is urgently needed. In our previous work DNA vaccines encoding secreted proteins Ag85B and MPT64 have been reported to protect mice from following H37Rv challenge by prompting the Th1 response and we consider whether these vaccines have the therapeutic effect through the same mechanism. In the present study these two DNA vaccines were tested in a mouse tuberculosis model to confirm their immunotherapeutic effect. C57BL/6 mice infected with Mycobacterium tuberculosis were treated with pCDNA3.1, pcD85B, pcDMPT64, pcD85B plus pcDMPT64, respectively. The numbers of viable bacteria in lung and spleen were counted as log(10)CFU/g. The level of IFN-gamma, IL-4 and TNF-alpha released by spleen lymphocytes stimulated with PPD was detected with ELISA. Lungs and spleens were harvested for pathological analysis. The pcD85B group reduced the pulmonary and splenic bacterial loads of 1.2 and 0.7 logs, respectively compared with that of control mice, but the difference between pcDMPT64 group and control mice was not significant. Vaccination with pcD85B induced high level of IFN-gamma and TNF-alpha. No change of IL-4 level was found in all groups. The pathological change in lung in pcD85B group was slight, alveolar wall structure is clear and the lesions are constrained, while that in control group was extensive, alveoli and interalveolar septae are effaced. And there was no special change in spleen in all groups. In conclusion, Ag85B DNA vaccination has immunotherapeutic effects, and the effects may be associated with a switch to Th1 response and prompting production of cytokine TNF-alpha and INF-gamma synchronously. Therefore, MPT64 DNA vaccination has no immunotherapeutic effect on mice tuberculosis. Rather, the effects may be associated with its disability in switching improper immune status and with recalling a strong and early specific memory immune response against tuberculosis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16053938     DOI: 10.1016/j.vaccine.2005.05.035

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  5 in total

Review 1.  Tuberculosis vaccine research in China.

Authors:  Douglas B Lowrie
Journal:  Emerg Microbes Infect       Date:  2012-07-25       Impact factor: 7.163

2.  Ag85A/ESAT-6 chimeric DNA vaccine induces an adverse response in tuberculosis-infected mice.

Authors:  Yan Liang; Xuejuang Bai; Junxian Zhang; Jingying Song; Yourong Yang; Qi Yu; Ning Li; Xueqiong Wu
Journal:  Mol Med Rep       Date:  2016-06-03       Impact factor: 2.952

3.  Designing and Construction of a Cloning Vector Containing mpt64 Gene of Mycobacterium tuberculosis.

Authors:  Hosna Zare; Ehsan Aryan; Shadi Alami; Atieh Yaghoubi; Roghayeh Teimourpour; Zahra Meshkat
Journal:  Tanaffos       Date:  2018-03

4.  Adjunctive immunotherapy with α-crystallin based DNA vaccination reduces Tuberculosis chemotherapy period in chronically infected mice.

Authors:  Priyanka Chauhan; Ruchi Jain; Bappaditya Dey; Anil K Tyagi
Journal:  Sci Rep       Date:  2013       Impact factor: 4.379

5.  Intranasal DNA Vaccine for Protection against Respiratory Infectious Diseases: The Delivery Perspectives.

Authors:  Yingying Xu; Pak-Wai Yuen; Jenny Ka-Wing Lam
Journal:  Pharmaceutics       Date:  2014-07-10       Impact factor: 6.321

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.